Intellia Therapeutics Stock Investor Sentiment
| NTLA Stock | USD 9.58 0.44 4.81% |
About 63% of all Intellia Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Intellia Therapeutics suggests that some traders are interested. The current market sentiment, together with Intellia Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Intellia Therapeutics stock news signals to limit their universe of possible portfolio assets.
Comfort Level 63
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Intellia Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Intellia Therapeutics.
News SentimentNeutral | Hype SentimentBullish | Insider SentimentDisposing |
Intellia Historical Sentiment
Although Intellia Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Intellia, such as negative comments on social media and news outlets, may cause fear in the market and push Intellia Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Intellia.
Intellia |
Intellia Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Intellia Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Intellia Therapeutics Historical Investor Sentiment
Investor biases related to Intellia Therapeutics' public news can be used to forecast risks associated with an investment in Intellia. The trend in average sentiment can be used to explain how an investor holding Intellia can time the market purely based on public headlines and social activities around Intellia Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Intellia Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intellia Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Intellia Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Intellia Therapeutics.
Far too much social signal, news, headlines, and media speculation about Intellia Therapeutics that are available to investors today. That information is available publicly through Intellia media outlets and privately through word of mouth or via Intellia internal channels. However, regardless of the origin, that massive amount of Intellia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Intellia Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Intellia Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Intellia Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Intellia Therapeutics alpha.
Intellia Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 7850 shares by Leonard John M of Intellia Therapeutics subject to Rule 16b-3 | 12/31/2024 |
2 | Disposition of 556 shares by Clark Eliana of Intellia Therapeutics at 12.03 subject to Rule 16b-3 | 01/02/2025 |
3 | Disposition of 7422 shares by Clark Eliana of Intellia Therapeutics at 12.18 subject to Rule 16b-3 | 01/03/2025 |
4 | Insider Trading | 01/13/2025 |
5 | Acquisition by Goff Brian of 15409 shares of Intellia Therapeutics subject to Rule 16b-3 | 01/31/2025 |
6 | ROSEN, SKILLED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action NTLA | 02/24/2025 |
7 | Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and ... | 02/27/2025 |
8 | Intellia Therapeutics Inc Faces Securities Fraud Class Action Lawsuit | 03/03/2025 |
9 | Bragar Eagel Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed ... | 03/05/2025 |
10 | Intellia Therapeutics Now Covered by HC Wainwright | 03/06/2025 |
11 | Truist Financial Cuts Intellia Therapeutics Price Target to 50.00 | 03/07/2025 |
12 | INTELLIA THERAPEUTICS, INC. DEADLINE ALERT Bernstein Liebhard LLP Reminds Intellia Therapeutics, Inc. Investors of Upcoming Deadline | 03/10/2025 |
13 | NTLA INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Intellia ... | 03/12/2025 |
14 | Levi Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc. Shareholders | 03/13/2025 |
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |